Eli Lilly agreed to acquire global rights to MeiraGTx’s AAV-AIPL1 gene therapy for Leber congenital amaurosis 4 and struck an expanded AI drug-discovery collaboration with Insilico Medicine. Lilly will pay $75 million upfront for the retinal gene program and up to $400 million in milestones, and it announced a multi-year discovery partnership with Insilico that could exceed $100 million in value. Lilly said the MeiraGTx asset has shown unprecedented visual restoration in children with AIPL1 mutations and will join Lilly’s growing genetic-medicine efforts after its Adverum acquisition. The Insilico tie shifts Lilly from customer to co-developer on AI-enabled target discovery, signaling pharma’s increasing reliance on generative AI platforms to accelerate early research. These moves expand Lilly’s genetic medicine footprint and operationalize AI across its pipeline.